Abingworth LLP is a transatlantic bioscience investment firm founded in 1973 by London stockbrokers Peter Dicks and Hon. Anthony Montagu. Initially established as Abingworth Management Ltd., the firm has been instrumental in transforming scientific discoveries into medical treatments for over three decades.

Abingworth's investment strategy focuses on early-stage life science and healthcare services companies, with a particular emphasis on biotechnology. The firm has a history of successful investments, including early stakes in Apple Computer and Silicon Graphics. In August 2022, Abingworth was acquired by The Carlyle Group, bringing approximately $2 billion in assets under management.

The firm's offices are located in London, Boston, and San Francisco, providing transatlantic access to key biotech hubs. Abingworth's portfolio includes over a hundred companies, and it has pioneered approaches such as Venture Investments in Public Equities (VIPEs) and Clinical Co-Development to support the growth of its portfolio companies.